Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Three GPIIb/IIIa antagonists are available in the market. In France, as in many countries, their acquisition costs strongly differ. The objective of this study was to analyze how economic criteria-beyond the acquisition cost-should be factored in, when choosing a GPIIb/IIIa antagonist.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Pharm World Sci

Title: Pharmacy world & science : PWS

Publisher: Springer Science and Business Media LLC

ISSN: 0928-1231

ISSN (Print): 0928-1231

Publication date (Electronic): Apr 2005

Volume: 27

Issue: 2

Affiliations

[1 ] CLP-Santé, 9-11 rue du Mont Aigoual, 75015 Paris, France. claude.lepen@clp-sante.fr

Article

DOI: 10.1007/s11096-004-2269-1

PubMed ID: 15999917

SO-VID: ca50026e-1719-4ab3-a760-1e838c54de3f

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.